The ALS Centre Netherlands is the centre of expertise on ALS, PLS and PMA in the Netherlands. The centre is a cooperation of the University Medical Centre Utrecht and the Amsterdam Medical Centre. The centre schedules all diagnostic research and consultations for each patient on one day. More than 500 patients are diagnosed with ALS, PLS, PMA or one of its mimics each year. The ALS Centre Netherlands initiated Project Mine (www.projectmine.com), the largest research of the genetic basis of ALS worldwide. Additionally, research focuses on epidemiology, brain imaging and cognitive functioning of ALS patients.
| ALS Centre Netherlands | |
|---|---|
| Foundation year | 1998 |
| Director | Prof. dr. Leonard van den Berg |
| Principal investigator | Prof. dr. Leonard H. van den Berg, Prof. dr. Jan Veldink, Prof. dr. Jeroen Pasterkamp |
| Contact information | |
|---|---|
| Address | Heidelberglaan 100 |
| Phone | 0031 631 11 85 13 |
| info@als-centrum.nl | |
| Website | Visit the website |
Publications
- Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; for the EMPOWER investigators. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology 2013 Nov;12(11):1059-67
- Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, Nicholson G, Ravits J, Shaw PJ, Swash M, Talbot K, Traynor BJ, van den Berg LH, Veldink JH, Vucic S, Kiernan MC. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12(3):310-22.
- Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, Christiansen MW, Fairfax BP, Schramm K, Powell JE, Zhernakova A, Zhernakova DV, Veldink JH, Van den Berg LH, Karjalainen J, Withoff S, Uitterlinden AG, Hofman A, Rivadeneira F, \’t Hoen PA, Reinmaa E, Fischer K, Nelis M, Milani L, Melzer D, Ferrucci L, Singleton AB, Hernandez DG, Nalls MA, Homuth G, Nauck M, Radke D, Völker U, Perola M, Salomaa V, Brody J, Suchy-Dicey A, Gharib SA, Enquobahrie DA, Lumley T, Montgomery GW, Makino S, Prokisch H, Herder C, Roden M, Grallert H, Meitinger T, Strauch K, Li Y, Jansen RC, Visscher PM, Knight JC, Psaty BM, Ripatti S, Teumer A, Frayling TM, Metspalu A, van Meurs JB, Franke L. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nature Genet 2013;45(10):1238-43.
- Van Blitterswijk M, Wang ET, Friedman BA, Keagle PJ, Lowe P, Leclerc AL, van den Berg LH, Housman DE, Veldink JH, Landers JE. Characterization of FUS Mutations in Amyotrophic Lateral Sclerosis Using RNA-Seq. PLoS One 2013;8(4):e60788.
- Blauw HM, Barnes CP, van Vught PW, van Rheenen W, Verheul M, Cuppen E, Veldink JH, van den Berg LH. SMN1 gene duplications are associated with sporadic ALS. Neurology. 2012 Mar 13;78(11):776-80. Epub 2012 Feb 8. PubMed PMID: 22323753; PubMed Central PMCID: PMC3304946.
Have a look at the researchgate pages with full-text publications
Restricted information
| Serving population | |
|---|---|
| Serving population | 100.000 to 1.000.000 |
| Patient resources | |
|---|---|
| Population based register | Yes |
| Clinic based register | Yes |
| Geographically matched controls | Yes |
| Number of skin samples | 57 |
| Number of spinal cord samples | 25 |
| Number of brain samples | 25 |
| Number of IPS cell samples | in development |
Banks
| Type | ALS Patients | Controls | Other |
|---|---|---|---|
| DNA Bank | 2650 | 3200 | 0 |
| Serum Bank | 2160 | 3080 | 0 |
| RNA Bank | 500 | 2380 | 0 |
| MRI | 443 | 409 | 105 PSMA, 81 PLS, 83 mimics |
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | Yes |
| Neuro imaging | Yes |
| Neuro psychology | Yes |
| Neuro pathology | Yes |
| Genomics | Yes |
| Transcriptomics | Yes |
| Metabolomics | Yes |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| Masitinib trial ABscience (AB10015) | phase 2/3 | 10 |
| CHDR1417 | phase 1 trial | 18 |
| Levals (ODM-109) | phase 2a Levosimendan | 5 |
| TW001 Treeway | phase 1 trial oral formulation edaravone | 10 |
| Vitality-ALS Cytokinetics | phase 3 Tirasemtiv trial | 10 |
| VEGF trial NEWRON Sweden (sNN0029) | phase 1 | 5 |
| Benefit Trial 2013 (CK-2017357) Cytokinetics | Tirasemtiv trial | 12 |
| Ozanezumab 2014 (GSK1223249) | phase 2 | 22 |
| Envision 2012 (KNS-760704) | phase 3 Extension Study of Dexpramipexole in ALS | 28 |
| EMPOWER 2011 (KNS-760704) | Dexpramipexole in ALS, phase 3 | 28 |
| Alstar 2009 | Alstar 2009 | 13 |
| ONO-2506 (Ono Pharmaceutical Co. Ltd) | ONO 2007 | 26 |
Clinical Trials - Investigator initiated
| Name | Type | Patients |
|---|---|---|
| LITRA 2008 (Lithium) | LITRA 2008 (Lithium) | 130 |
| Natriumvalproaat 2005 | Natriumvalproaat 2005 | 188 |